- Home
- FTDR vs LGND Comparison
FTDR vs LGND Comparison
Compare FTDR & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | LGND |
|---|---|---|
| Founded | 1971 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTDR | LGND |
|---|---|---|
| Price | $61.75 | $234.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $67.20 | ★ $247.29 |
| AVG Volume (30 Days) | ★ 533.3K | 179.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $2,093,000,000.00 | N/A |
| Revenue This Year | $5.97 | $1.25 |
| Revenue Next Year | $5.82 | $19.41 |
| P/E Ratio | ★ $17.74 | $76.27 |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $40.15 | $98.90 |
| 52 Week High | $70.77 | $247.38 |
Technical Indicators
Market Signals| Indicator | FTDR | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 60.36 |
| Support Level | $55.70 | $180.85 |
| Resistance Level | $63.56 | N/A |
| Average True Range (ATR) | 2.03 | 10.11 |
| MACD | 0.39 | 1.34 |
| Stochastic Oscillator | 78.68 | 67.93 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.